DNL Diurnal Group

Hardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum

Hardman & Co Research
Hardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum

07-Oct-2021 / 11:15 GMT/BST

Hardman & Co Life Sciences Investor Forum company research: 

Diurnal Group (DNL)

On 23 September we were delighted to host our second Life Sciences Investor Forum. At the live event, CEO, Martin Whitaker, answered questions on the business growth and M&A plans for Diurnal's portfolio as well the commercial rights to Chronocort(R) in the US and the expected changes when the drug is de-risked.

 We would like to share with you the research note and slide pack, along with the recording of the presentation.

| |

If you are interested in meeting the company, you can register your interest by clicking .

To contact us:

Hardman & Co
1 Frederick's Place

London

EC2R 8AE

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall



5

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1239110  07-Oct-2021 

fncls.ssp?fn=show_t_gif&application_id=1239110&application_name=news&site_id=research_pool
EN
07/10/2021

Underlying

DNLDiurnal Group

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Diurnal Group

Sean Conroy
  • Sean Conroy
DNL DIURNAL GROUP

Diurnal Group - Termination of coverage

Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP), Silver One Resources (SVE), Induction Healthcare (INHC) and Axiom European Financial Debt (AXI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

02/01/23 February 1, 2023 1 EN
Keith Hiscock ... (+4)
  • Keith Hiscock
  • Mark Thomas
  • Martin Hall
  • Mike Foster
TRX Tissue Regenix ...
FEV Fidelity Europe... ... (+19)

The Hardman & Co Monthly: September 2022

Feature article: Macro issues dominate investor sentiment - Some basics for investors The big topics in the investment world at the moment seem to be macroeconomic. With that in mind, we thought it would be useful to revisit some of the basics of the terms being used in the current environment, and to remind investors of the things to look out for (indeed, many younger investors may not have come across some of these influences in their investing lifetime): • Recession does not affect ...

TRX TISSUE REGENIX GROUP
FEV FIDELITY EUROPEAN VALUES PLC
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FSV FIDELITY SPECIAL VALUES PLC
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
AVO ADVANCED ONCOTHERAPY
RECI REAL ESTATE CREDIT INVESTMENTS
APP APPRECIATE GROUP
PANR PANTHEON RESOURCES
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
OCI OAKLEY CAPITAL INVESTMENTS
DNL DIURNAL GROUP
ICGT ICG ENTERPRISE TRUST
CIZ CIZZLE BIOTECHNOLOGY HLDGS PLC
OCL OAKLEY CAPITAL
09/05/22 September 5, 2022 1 EN
Sean Conroy
  • Sean Conroy
DNL DIURNAL GROUP

Diurnal Group - Proposed acquisition by Neurocrine Biosciences

Diurnal has announced that it has agreed to an acquisition by Neurocrine Biosciences (US-based biopharmaceutical player) for a cash consideration of £48.3m or 27.5p per share. The proposed acquisition consideration is a c 144% premium to the closing price of 11.25p on 26 August. Although the acquisition is subject to shareholder approval by both companies, the transaction is likely to close by late October or early November. Neurocrine is also focused on the endocrine space (in addition to neuro...

08/31/22 August 31, 2022 1 EN
 PRESS RELEASE
Free
DNL DIURNAL GROUP

Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group p...

Maitland Institutional Services Limited (MISL) Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc 30-Aug-2022 / 12:32 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: MI Chelverton UK Equity Growth Fund ...

August 30, 2022 1 EN
Brian Moretta ... (+5)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
  • Mike Foster
  • Nigel Hawkins
TRX Tissue Regenix ...
FEV Fidelity Europe... ... (+21)

The Hardman & Co Monthly: August 2022

Feature article: Utility regulation – Changes afoot - Patching up a tainted model While the gas supply crisis – and its price implications – have dominated the UK price regulated sectors in recent months, other issues have arisen that have seriously tainted the price regulation system itself. Indeed, it is fair to ask whether it is ‘’fit for purpose’’. Back in 1984, price regulation, via an unsophisticated RPI-x formula, was introduced to prevent the privatised British Telecom (BT) from abusin...

TRX TISSUE REGENIX GROUP
FEV FIDELITY EUROPEAN VALUES PLC
IBT INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FCSS FIDELITY CHINA SPECIAL SITUATIONS PLC
ARBB ARBUTHNOT BANKING GROUP
FJV FIDELITY JAPAN TRUST
FAS FIDELITY ASIAN VALUES PLC
CLIG CITY OF LONDON INVESTMENT GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
APP APPRECIATE GROUP
PANR PANTHEON RESOURCES
VTAS VOLTA FINANCE (GBP)
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
OCI OAKLEY CAPITAL INVESTMENTS
DNL DIURNAL GROUP
PCA PALACE CAPITAL
ICGT ICG ENTERPRISE TRUST
BBGI BBGI GLOBAL INFRASTRUCTURE
CIZ CIZZLE BIOTECHNOLOGY HLDGS PLC
OCL OAKLEY CAPITAL
08/02/22 August 2, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch